Clinical trial

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

NCT04676997

Study summary

ClinicalTrials.gov

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention Camrelizumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Nab paclitaxel Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Epirubicin Normalized identity: epirubicin View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cyclophosphamide Normalized identity: cyclophosphamide View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2020-05-20

PhasePHASE2

Conditions

Triple Negative Breast Cancerunresolved

Interventions

CamrelizumabBIOLOGICAL

Nab paclitaxelDRUG

EpirubicinDRUG · verified · RxNorm: epirubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

Sponsors & collaborators

Shandong Cancer Hospital and Institutelead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Mapped research locations

JinanShandong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04676997 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.